IMRT 2018

…..and keeping in mind this….

„Nivolumab versus Everolimus in advanced renal cell carcinoma“

Motzer et al., NEJM, published online a few days ago

…ok, that was the moniker in last year‘s slide. Now it is already a year ago and the first combination studies between CP-inhibition and RT are in Phase III for head and neck and Phase II for kidney……….and you know the whole Lung story up to PACIFIC anyway…..one of the reasons some national debts are out of contro……..